In summary, through the gene differential expression analysis, functional enrichment analysis, and PPI analysis of DEGs in AF and NAFLD we have successfully provided deeper insight to the molecular changes in AF and NAFLD pathogenesis, and identified several potential candidate therapeutic changes, including CXCR2, PTPRC, CCR2, MNDA, NCF2, S100A9, S100A8, S100A12. These hub genes were mainly enriched in inflammation and immune related biological functions and pathways. The gene discussed is S100A8; the disease is metabolic dysfunction-associated steatotic liver disease.